Advertisement

High-Dose, Long-Term, Continuous Subcutaneous Infusion of SMS 201–995 (Sandostatin®) in Acromegaly

  • S. Chatterjee
  • M. C. White
  • N. Møller
  • K. Hall
  • M. J. Dunne
  • E. R. Baister
  • P. Kendall-Taylor
Conference paper

Abstract

Acute and chronic studies have demonstrated the effectiveness of the long-acting somatostatin analogue SMS 201–995 (Sandostatin®) in the treatment of acromegaly. Daily doses of 100–300 µg Sandostatin given as multiple injections in most cases induce satisfactory suppression of GH release. No consistent shrinkage of the pituitary tumour has been demonstrated.

Keywords

Growth Hormone Pituitary Tumour Growth Hormone Level Growth Hormone Response Growth Hormone Release 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag, Berlin Heidelberg 1988

Authors and Affiliations

  • S. Chatterjee
    • 1
    • 2
  • M. C. White
    • 1
    • 2
  • N. Møller
    • 1
    • 2
  • K. Hall
    • 1
    • 2
  • M. J. Dunne
    • 1
    • 2
  • E. R. Baister
    • 1
    • 2
  • P. Kendall-Taylor
    • 1
    • 2
  1. 1.Departments of Medicine and RadiologyUniversity of Newcastle upon TyneUK
  2. 2.Sandoz Laboratories LtdBasleSwitzerland

Personalised recommendations